Danaher Corporation (NYSE:DHR) has achieved a significant 16% rise in its share price over the last three months, even as it faces a historical downturn of 13% over the past three years. With a quarterly earnings conference call set for January 28, 2026, the company will present conservative revenue growth projections of 3-6% for 2026, alongside strong insights from Goldman Sachs, which has issued a 'Buy' rating and anticipates a 9.2% organic growth in its lucrative Biotechnology division. This growth potential, coupled with a forecasted 77% profit increase in the coming years, marks Danaher as a key player among large-cap stocks.
“Danaher Corporation (NYSE:DHR) share price · has gained · 16% · last three months”
“Danaher Corporation (NYSE:DHR) share price · is down · 13% · last three years”
“Danaher Corporation · will webcast · quarterly earnings conference call · for the fourth quarter 2025 on January 28, 2026”
“Danaher Corporation · will discuss · financial performance · during the earnings call”
“Danaher's earnings press release · will be posted to · the Investors section of Danaher's website · beginning at 6:00 a.m. ET on the date of the earnings call”
“Danaher Corporation · is committed to · improving human health · through science and technology”
“Danaher's approximately 63,000 associates worldwide · help ensure that · Danaher is improving quality of life · for billions of people today”
“Danaher Corporation · has been benefiting from · strength in its Biotechnology segment · true”
“Danaher Corporation (NYSE:DHR) · is one of the · 14 Best Large Cap Stocks to Invest In Now”
“Goldman Sachs · started covering · Danaher Corporation (NYSE:DHR)”
“Goldman Sachs · gave · Danaher Corporation (NYSE:DHR) a Buy rating”
“Danaher Corporation (NYSE:DHR) · has a strong · $6 billion bioprocessing franchise”
